Tiger Brokers

Artelo Biosciences initiates non-clinical study of ART27.13 for GLP-1-related muscle loss; incretin market climbs to $200 billion by 2030 forecast

Reuters
Yesterday
<a href="https://laohu8.com/S/ARTL">Artelo Biosciences</a> initiates non-clinical study of ART27.13 for GLP-1-related muscle loss; incretin market climbs to $200 billion by 2030 forecast
  • Artelo announced initiation of a non-clinical study evaluating ART27.13 in models relevant to muscle preservation associated with GLP-1 receptor agonist therapy.
  • Prior results were referenced from the Phase 2 CAReS trial in cancer anorexia and cachexia, where ART27.13 was associated with improvements in lean body mass and physical activity.
  • The company also cited published independent peer-reviewed research describing ART27.13 as a superagonist in a kinetic multiplex assay of clinical GPCR agonists.
  • Artelo reported filing a provisional patent application covering cannabinoid receptor agonism to prevent or mitigate muscle loss associated with GLP-1 therapy.
  • A third-party, fully funded clinical study is planned to start in Q2 2026 to evaluate ART27.13 in glaucoma patients, and results were not reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603251605PRIMZONEFULLFEED9678547) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10